2,10-dimethoxy-9-(phenylsulfonyloxy)-5,6,7,8,13,13a-hexahydroisoquinolino[3,2-a]isoquinolin-3-yl 5-((5S,1R,2R)-7-oxo-3-thia-6,8-diazabicyclo[3.3.0]oct-2-yl)pentanoate | 1233353-79-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 原小檗碱生物碱及其衍生物
• 英文名称: 2,10-dimethoxy-9-(phenylsulfonyloxy)-5,6,7,8,13,13a-hexahydroisoquinolino[3,2-a]isoquinolin-3-yl 5-((5S,1R,2R)-7-oxo-3-thia-6,8-diazabicyclo[3.3.0]oct-2-yl)pentanoate
• 英文别名: 2,10-dimethoxy-9-(phenylsulfonyloxy)-5,6,7,8,13,13a-hexahydroisoquino[3,2-a]isoquinolin-3-yl 5-((5S,1R,2R)-7-oxo-3-thia-6,8-diazabicyclo[3.3.0]oct-2-yl)pentanoate；[9-(benzenesulfonyloxy)-2,10-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinolin-3-yl] 5-[(3aR,4R,6aS)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate
• CAS: 1233353-79-1
• 化学式: C₃₅H₃₉N₃O₈S₂
• 分子量: 693.842
• InChiKey: OUAWBBFCNCZGRA-QNDXLARDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  48
• 可旋转键数：
  12
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  166
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  3-hydroxy-2,10-dimethoxy-5,6,7,8,13,13a-hexahydroisoquinolino[2,1-b]isoquinolin-9-yl benzenesulfonate 、 生物素杂质27 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2,10-dimethoxy-9-(phenylsulfonyloxy)-5,6,7,8,13,13a-hexahydroisoquinolino[3,2-a]isoquinolin-3-yl 5-((5S,1R,2R)-7-oxo-3-thia-6,8-diazabicyclo[3.3.0]oct-2-yl)pentanoate
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY
  [FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA NASH, DE LA NAFLD ET DE L'OBÉSITÉ

  摘要：

  目前的技术涉及使用I、II、III、IV、V和/或VI式化合物治疗NASH、NAFLD和/或肥胖的方法。这些方法包括向患有非酒精性脂肪肝炎（NASH）、非酒精性脂肪肝病（NAFLD）和/或肥胖的受试者施用这种化合物的治疗有效剂量。

  公开号：

  WO2021067490A1

文献信息

• Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
  申请人：Liu Haiyan

  公开号：US20110009628A1

  公开（公告）日：2011-01-13

  The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.

  目前的技术涉及到公式I-VI的化合物以及制备和使用这些化合物的方法。使用方法包括预防和治疗高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性和代谢综合征。本文披露的化合物还可以增加高密度脂蛋白胆固醇（HDL-C），降低总胆固醇、低密度脂蛋白胆固醇（LDL-C）和甘油三酯，并增加肝LDL受体表达，抑制PCSK9表达，并激活AMP激活蛋白激酶。
• [EN] CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS<br/>[FR] DÉRIVÉS DE CORYDALINE UTILES DANS LA RÉDUCTION DES TAUX LIPIDIQUES
  申请人：CVI PHARMACEUTICALS LTD

  公开号：WO2010075469A1

  公开（公告）日：2010-07-01

  The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.

  目前的技术涉及到公式（V）和（VI）的化合物以及制备和使用这些化合物的方法。使用方法包括预防和治疗高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性和代谢综合征。本文披露的化合物还能降低总胆固醇、LDL-胆固醇和甘油三酯，增加肝LDL受体表达，抑制PCSK9表达，并激活AMP激活的蛋白激酶。
• ISOQUINOLINYL-CONTAINING ALKALOID COMPOUNDS AND COMPOSITIONS USEFUL FOR REDUCING LIPID LEVELS
  申请人：CVI Pharmaceuticals Limited

  公开号：EP2370434B1

  公开（公告）日：2014-09-17
• COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS
  申请人：Liu Haiyan

  公开号：US20120004223A1

  公开（公告）日：2012-01-05

  The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.
• COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY
  申请人：LIU Jingwen

  公开号：US20220387403A1

  公开（公告）日：2022-12-08

  The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound